Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Wood, G. De Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyorala, et al.
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.
Atherosclerosis, 140 (1998), pp. 199-270
[2.]
Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular.
Clin Invest Arterioscler, 12 (2000), pp. 125-152
[3.]
Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular.
Ilib, (2000),
[4.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Jama, 285 (2001), pp. 2486-2497
[5.]
E. Ros.
Inhibidores de la HMG-CoA reductasa. Mecanismo de acción, eficacia e indicaciones.
Clin Invest Arterioscler, 14 (2002), pp. 3-14
[6.]
T.A. Pearson, I. Laurora, H. Chu, S. Kafonek.
The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
Arch Intern Med, 160 (2000), pp. 459-467
[7.]
Euroaspire II Study Group.
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from the EUROASPIRE II Euro Heart Survey Programme.
Eur Heart J, 22 (2001), pp. 554-572
[8.]
P. Jones, S. Kafonek, I. Laurora, D. Hunninghake.
for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study).
Am J Cardiol, 81 (1998), pp. 582-587
[9.]
T.C. Andrews, C.M. Ballantyne, J.A. Hsia, J.H. Kramer.
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Am J Med, 111 (2001), pp. 185-191
[10.]
Heart Protection Study Collaborative Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial.
Lancet, 360 (2002), pp. 7-22
[11.]
M.H. Davidson.
Statin trials in progress: unanswered questions.
Curr Atheroscler Rep, 3 (2001), pp. 9-13
[12.]
R.C. Pasternak, S.C. Smith, C.N. Bairey-Mer, S.M. Grundy, J.I. Cleeman, C. Lenfant.
Acc/aha/nhbli Clinical Advisory on the use and safety of statins.
J Am Coll Cardiol, 40 (2002), pp. 567-572
[13.]
J.A. Farmer.
Learning from the cerivastatin experience.
Lancet, 358 (2001), pp. 1383-1385
[14.]
G.R. Thompson, F. O’Neill, M. Seed.
Why some patients respond poorly to statins and how this might be remedied.
Eur Heart J, 23 (2002), pp. 200-206
[15.]
J.M. Dietschy, S.D. Turley, D.K. Spady.
Role of the liver in the maintenance of cholesterol and low-density lipoprotein homeostasis in different animal species, including humans.
J Lipid Res, 34 (1993), pp. 1637-1659
[16.]
E. Ros.
Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk.
Atherosclerosis, 151 (2000), pp. 357-379
[17.]
T. Sudhop, K. Von Bergmann.
Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia.
Drugs, 62 (2002), pp. 2333-2347
[18.]
S.D. Turley, J.M. Dietschy.
Sterol absorption by the small intestine.
Curr Opin Lipidol, 14 (2003), pp. 233-240
[19.]
S.M. Bosner, L.G. Lange, W.F. Stenson, R.E. Ostlund Jr..
Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry.
J Lipid Res, 40 (1999), pp. 302-308
[20.]
M.C. Carey, D.M. Small.
The characteristics of mixed micellar solutions with particular reference to bile.
Am J Med, 49 (1970), pp. 590-598
[21.]
R.E. Ostlund Jr..
Phytosterols in human nutrition.
Annu Rev Nutr, 22 (2002), pp. 533-549
[22.]
G. Salen, E.H. Ahrens Jr., S.M. Grundy.
Metabolism of b-sitosterol in man.
J Clin Invest, 49 (1970), pp. 952-967
[23.]
T.A. Miettinen, R.S. Tilvis, Y.A. Kesaniemi.
Serum plant sterol and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.
Am J Epidemiol, 131 (1990), pp. 20-31
[24.]
W.E. Connor, D.S. Lin.
Absorption and transport of shellfish sterols in human subjects.
Gastroenterology, 81 (1981), pp. 276-284
[25.]
G. Schmitz, T. Langmann, S. Helmerl.
Role of ABCG1 and other ABCG family members in lipid metabolism.
J Lipid Res, 42 (2001), pp. 1513-1520
[26.]
K.E. Berge, H. Tian, G.A. Graf, L. Yu, N.V. Grishin, J. Schultz, et al.
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.
Science, 290 (2000), pp. 1771-1775
[27.]
M.H. Lee, K. Lu, S. Hazard, H. Yu, S. Shulenin, H. Hidaka, et al.
Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption.
Nat Genet, 27 (2001), pp. 79-83
[28.]
C. Joyce, K. Skinner, R.A. Anderson, L.L. Rudel.
Acyl-coenzyme A: cholesterol acyltransferase 2.
Curr Opin Lipidol, 10 (1999), pp. 89-95
[29.]
A. Chawla, J.J. Repa, R.M. Evans, D.J. Mangelsdorf.
Nuclear receptors and lipid physiology: opening the X-files.
Science, 294 (2001), pp. 1866-1870
[30.]
F.J. Field, N.T.P. Kam, S.N. Mathur.
Regulation of cholesterol metabolism in the intestine.
Gastroenterology, 99 (1990), pp. 539-551
[31.]
D.A. Gordon.
Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly.
Curr Opin Lipidol, 8 (1997), pp. 131-137
[32.]
J.R. Wetterau, L.P. Aggerbeck, M.E. Bouma, C. Eisenberg, A. Munck, M. Hernier, et al.
Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia.
Science, 258 (1992), pp. 999-1001
[33.]
D.J. McNamara, R. Kolb, T.S. Parker, H. Batwin, P. Samuel, C.D. Brown, et al.
Heterogeneity of cholesterol homeostasis in man: response to changes in dietary fat quality and cholesterol quantity.
J Clin Invest, 79 (1987), pp. 1729-1739
[34.]
P.J.H. Jones, A.S. Pappu, L. Hatcher, Z.C. Li, D.R. Illingworth, W.E. Connor.
Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels.
Arterioscler Thromb Vasc Biol, 16 (1996), pp. 1222-1228
[35.]
P. Hopkins.
Effects of dietary cholesterol on serum cholesterol: a meta-analysis and review.
Am J Clin Nutr, 55 (1992), pp. 1060-1070
[36.]
E. Ros.
El colesterol de la dieta y su escasa influencia sobre la colesterolemia y el riesgo cardiovascular.
Clin Invest Arterioscler, 12 (2000), pp. 20-26
[37.]
S.Q. Ye, P.O. Kwiterowich Jr..
Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol.
Am J Clin Nutr, 72 (2000), pp. S1275-S1284
[38.]
K.E. Berge, K. Von Bergmann, D. Lutjohann, R. Guerra, S.M. Grundy, H.H. Hobbs, et al.
Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8.
J Lipid Res, 43 (2002), pp. 486-494
[39.]
K. Von Bergmann, D. Lutjohann, B. Lindenthal, A. Steinmetz.
Efficiency of intestinal cholesterol absorption in humans is not related to apoE phenotype.
J Lipid Res, 44 (2003), pp. 193-197
[40.]
R.E. Ostlund Jr., S.B. Racette, A. Okeke, W.F. Stenson.
Phytosterols that are naturally present in commercial corn oil significantly reduce cholesterol absorption in humans.
Am J Clin Nutr, 75 (2002), pp. 1000-1004
[41.]
E.R.M. Eckhardt, D.Q.H. Wang, J.M. Donovan, M.C. Carey.
Dietary sphingomyelin suppresses cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers.
Gastroenterology, 122 (2002), pp. 948-956
[42.]
H. Gylling, T.A. Miettinen.
Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption.
J Lipid Res, 43 (2002), pp. 1472-1476
[43.]
G.V. Vahouny, R. Tombes, M.M. Cassidy, D. Kritchevsky, L.L. Gallo.
Dietary fibers. V. Binding of bile salts, phospholipids and cholesterol from mixed micelles by bile acid sequestrants and dietary fibers.
Lipids, 15 (1980), pp. 1012-1018
[44.]
B. Flourie, N. Vidon, C.H. Florent, J.J. Bernier.
Effect of pectin on jejunal glucose absorption and unstirred layer thickness in normal man.
Gut, 25 (1984), pp. 936-941
[45.]
F.U. Beil, S.M. Grundy.
Studies on plasma lipoproteins during absorption of exogenous lecithin in man.
J Lipid Res, 21 (1980), pp. 525-536
[46.]
J.T. Knuiman, A.C. Beynen, M.B. Katan.
Lecithin intake and serum cholesterol.
Am J Clin Nutr, 49 (1989), pp. 266-268
[47.]
M.J. Armstrong, M.C. Carey.
Thermodymanic and molecular determinants of sterol solubilities in bile acid micelles.
J Lipid Res, 28 (1987), pp. 1144-1155
[48.]
M. Nissinen, H. Gylling, M. Vuoristo, T.A. Miettinen.
Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion.
Am J Physiol, 282 (2002), pp. G1009-G1015
[49.]
J. Plat, R.P. Mensink.
Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption.
Faseb j, 16 (2002), pp. 1248-1253
[50.]
E. Ros.
Introducción a los alimentos funcionales.
Med Clin (Barc), 116 (2001), pp. 617-619
[51.]
I. Plaza.
Los fitosteroles, el colesterol y la prevención de las enfermedades cardiovasculares.
Clin Invest Arterioscler, 13 (2001), pp. 209-218
[52.]
A.H. Lichtenstein, R.J. Deckelbaum.
for the American Heart Association Nutrition Committee. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for health professionals from the Nutrition Committee, American Heart Association.
Circulation, 103 (2001), pp. 1177-1179
[53.]
P. Samuel.
Treatment of hypercholesterolemia with neomycin - A time for reappraisal.
N Engl J Med, 301 (1979), pp. 595-597
[54.]
B. Mittendorfer, R.E. Ostlund Jr., B.W. Patterson, S. Klein.
Orlistat inhibits dietary cholesterol absorption.
Obes Res, 9 (2001), pp. 599-604
[55.]
W. Insull Jr., M. Koren, J. Davignon, D. Sprecher, H. Schrott, L.M. Keilson, et al.
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins in patients with combined hyperlipidemia.
Atherosclerosis, 157 (2001), pp. 137-144
[56.]
J.R. Wetterau, R.E. Gregg, T.W. Harrity, C. Arbeeny, M. Cap, F. Connolly, et al.
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHL rabbits.
Science, 282 (1998), pp. 751-754
[57.]
D.A. Burnett, M.A. Caplen, H.R. Davis Jr., R.E. Burrier, J.W. Clader.
2-Azetidinones as inhibitors of cholesterol absorption.
J Med Chem, 37 (1994), pp. 1733-1736
[58.]
A.L. Catapano.
Ezetimibe: a selective inhibitor of cholesterol absorption.
Eur Heart J, 3 (2001), pp. E6-E10
[59.]
C. Ballantyne.
Ezetimibe: efficacy and safety in clinical trials.
Eur Heart J Suppl, 4 (2002), pp. J5-J15
[60.]
M.H. Davidson.
Ezetimibe: a novel option for lowering cholesterol.
Expert Rev Cardiovasc Ther, 1 (2003), pp. 11-21
[61.]
B.G. Salisbury, H.R. Davis Jr., R.E. Burrier, D.A. Burnett, G. Boykow, M.A. Caplen, et al.
Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.
Atherosclerosis, 115 (1995), pp. 45-63
[62.]
M. Van Heek, C.F. France, D.S. Compton, R.L. McLeod, N.P. Yumibe, K.B. Alton, et al.
In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, and its glucuronide, SCH 60663.
J Pharmacol Exp Ther, 283 (1997), pp. 157-163
[63.]
M. Van Heek, H. Davis.
Pharmacology of ezetimibe.
Eur Heart J Suppl, 4 (2002), pp. J17-J20
[64.]
J.J. Repa, J.M. Dietschy, S.D. Turley.
Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5 or ABCG8 in the enterocyte.
J Lipid Res, 43 (2002), pp. 1864-1874
[65.]
M. Van Heek, C. Farley, D.S. Compton, L. Hoos, H.R. Davis.
Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.
Br J Pharmacol, 134 (2001), pp. 409-417
[66.]
T. Sudhop, D. Lütjohann, A. Kodal, M. Igel, D.L. Tribble, S. Shah, et al.
Inhibition of intestinal cholesterol absorption by ezetimibe in humans.
Circulation, 106 (2002), pp. 1943-1948
[67.]
G. Salen, K. Von Bergmann, P. Kwiterovitch, B. Musser, L. O’Grady, P. Stein, T. Musliner.
Ezetimibe is an effective treatment for homozygous sitosterolemia [abstract].
Circulation, 106 (2002), pp. II-185
[68.]
C.A. Dujovne, M.P. Ettinger, J.F. McNeer, L.J. Lipka, A.P. LeBeaut, R. Suresh, et al.
Efficacy and safety of a new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.
Am J Cardiol, 90 (2002), pp. 1092-1097
[69.]
R.H. Knopp, H. Gitter, T. Truitt, H. Bays, C.V. Manion, L.J. Lipka, et al.
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.
Eur Heart J, 24 (2003), pp. 729-741
[70.]
M. Van Heek, T.M. Austin, C. Farley, J.A. Cook, G.G. Tetzloff, H.R. Davis.
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
Diabetes, 50 (2001), pp. 1330-1335
[71.]
H.R. Davis, D.S. Compton, L. Hoos, G.G. Tetzloff.
Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 2032-2038
[72.]
H.R. Davis, K.K. Pula, K.B. Alton, R.E. Burrier, R.W. Watkins.
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs.
Metabolism, 50 (2001), pp. 1234-1241
[73.]
B. Kerzner, J. Corbelli, S. Sharp, L.J. Lipka, L. Melani, A. LeBeaut, et al.
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
Am J Cardiol, 91 (2003), pp. 418-424
[74.]
L. Melani, R. Mills, D. Hassman, R. Lipetz, L. Lipka, A. LeBeaut, et al.
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Eur Heart J, 24 (2003), pp. 717-728
[75.]
M.H. Davidson, T. McGarry, R. Bettis, L. Melani, L.J. Lipka, A.P. LeBeaut, et al.
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
J Am Coll Cardiol, 40 (2002), pp. 2125-2134
[76.]
C.M. Ballantyne, J. Houri, N. Notarbartolo, L. Melani, L.J. Lipka, R. Suresh, et al.
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial.
Circulation, 107 (2003), pp. 2409-2415
[77.]
C. Gagné, H.E. Bays, S.R. Weiss, P. Mata, K. Quinto, M. Melino, et al.
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
Am J Cardiol, 90 (2002), pp. 1084-1091
[78.]
P.N. Hopkins.
Familial hypercholesterolemia – Improving treatment and meeting guidelines.
Int J Cardiol, 89 (2003), pp. 13-23
[79.]
C. Gagné, D. Gaudet, E. Bruckert, Ezetimibe Study Group.
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Circulation, 105 (2002), pp. 2469-2475
[80.]
N. Stone.
Combination therapy: its rationale and the role of ezetimibe.
Eur Heart J Suppl, 4 (2002), pp. J21-J24
[81.]
E. Bruckert, P. Giral, P. Tellier.
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.
Circulation, 107 (2003), pp. 3124-3128
[82.]
M.H. Davidson.
Combination lipid-lowering therapy in diabetes.
Curr Diab Rep, 3 (2003), pp. 263-268
[83.]
T. Kosoglou, J.C. Fruchart, M. Guillaume, L.J.C. Pember, S. Sun, G. Picard, et al.
Coadministration of ezetimibe and fenofibrate leads to favorable effects on apo CIII and LDL subfractions [abstract].
Atherosclerosis Suppl, 2 (2001), pp. 89
[84.]
C. Baihent, M. Landry.
Study of Heart and Renal Protection (SHARP).
Kidney Internat, 63 (2003), pp. S207-S210
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.